Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Exuma Biotech Corp. is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 4 distinct examiners and 3 distinct art units. The busiest examiner identified is SPENCE, JENNIFER SUZANNE, who holds 1 busiest examiner pending office action.
Since there are 4 pending office actions and 4 distinct examiners, each action is assigned to a different person. However, the 3 distinct art units indicate that at least two of these 4 distinct examiners are working within the same art unit. This overlap suggests that while the individual examiners differ, some of the 4 pending office actions may be subject to the same art unit policies.
The busiest examiner, SPENCE, JENNIFER SUZANNE, handles 1 busiest examiner pending office action, which is the same number of actions as the other 3 distinct examiners. For the practitioner, this means the 4 pending office actions are evenly distributed. The prosecution strategy must account for the 4 distinct examiners and the technical requirements of the 3 distinct art units.
The Biotechnology & Pharmaceuticals area encompasses all 4 pending office actions. Practitioners should coordinate their approach across the 3 distinct art units to ensure consistency. Managing the feedback from 4 distinct examiners requires a comprehensive administrative strategy for this portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | TINSLEY, BRENDAN THOMAS | 134d overdue |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | BURKHART, MICHAEL D | 30d overdue |
| 17905649 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTE AGGREGATES | SPENCE, JENNIFER SUZANNE | — |
| 17684405 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTES AND/OR RETROVIRAL PARTICLES | JOHNSON, ALLISON MARIE | — |
| 16478377 | METHODS OF TRANSDUCING AND EXPANDING IMMUNE CELLS AND USES THEREOF | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1634 | 2 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905649 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTE AGGREGATES | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Non-Final OA | — | Pending | Sep 05, 2022 |
| 17684405 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTES AND/OR RETROVIRAL PARTICLES | JOHNSON, ALLISON MARIE | 1638 | §112Other | Final Rejection | — | Pending | Mar 01, 2022 |
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Non-Final OA | 134d overdue | Pending | Feb 28, 2022 |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | BURKHART, MICHAEL D | 1638 | §112 | Final Rejection | 30d overdue | Pending | Mar 01, 2021 |
| 16478377 | METHODS OF TRANSDUCING AND EXPANDING IMMUNE CELLS AND USES THEREOF | NICOL, ALEXANDER W | 1634 | §112Other | Non-Final OA | — | Pending | Jul 16, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial